Table 1 Characteristics of the included NMA.

From: Epidemiology Characteristics, Methodological Assessment and Reporting of Statistical Analysis of Network Meta-Analyses in the Field of Cancer

 

Category

Frequency

Proportion [%(95% CI)]

Language (n = 102)

English

92

90.20 (82.70–94.60)

Chinese

10

9.80 (5.40–17.30)

Journal quality (n = 102)

SCI

87

85.30 (77.00–90.90)

Non-SCI

15

14.70 (9.10–23.00)

CSCD

3

2.90 (1.00–8.70)

Non-CSCD

7

6.90 (3.30–13.70)

Impact factor (n = 87)

Median (IQR)

3.94 (2.721–5.635)

 

0.0–2.0

6

6.90 (3.10–14.50)

2.0–5.0

49

56.30 (45.80–66.30)

5.0–10.0

22

25.30 (17.30–35.40)

≥10.0

10

11.50 (6.30–20.10)

Publishing period (n = 56)

Median (IQR)

101 (47–187) day

 

1–30 days

12

21.40 (12.60–34.10)

30–60 days

10

17.90 (9.90–30.10)

60–90 days

4

7.10 (2.70–17.50)

90–150 days

12

21.40 (12.60–34.10)

≥150 days

19

33.90 (22.80–47.20)

Funding source (n = 60)

Unfunded (n = 14)

14

23.30 (14.30–35.60)

Industry-supported (n = 20)

20

33.30 (22.60–46.10)

Government-supported (n = 23)

23

38.30 (27.00–51.10)

Industry + Government (n = 3)

3

5.00 (1.60–14.40)

Number of author

Median (IQR)

6 (5–8)

 

Type of included study (n = 102)

RCT

100

98.00 (92.50–99.50)

Meta-analysis

2

2.00 (0.50–7.50)

Number of included trial

Median (IQR)

12 (7–23)

 

Intervention

Median (IQR)

5 (3–9)

 

Sample size (n = 102)

Median (IQR)

3605 (1950–7564)

 

Not reported

7

6.90 (3.30–13.70)

Outcome (n = 102)

Median (IQR)

3 (2–5)

 

Dichotomous

73

71.60 (62.10–79.50)

Continue

5

4.90 (2.10–11.20)

Survival time

79

77.50 (68.30–84.50)

Number of study arm (n = 102)

Two arms

50

49.00 (39.50–58.60)

Three arms

7

6.90 (3.30–13.70)

Two + Three arms/more

36

35.30 (26.70–45.00)

  1. Note: CI, confidence interval; NMA, network meta-analysis; SCI, Science Citation Index; CSCD, Chinese Science Citation Database; IQR, interquartile range.